Literature DB >> 9516449

Up-regulation of transforming growth factor (TGF)-beta receptors by TGF-beta1 in COLO-357 cells.

J Kleeff1, M Korc.   

Abstract

In the present study we investigated the actions of transforming growth factor (TGF)-beta1 on gene induction and cyclin-dependent kinase inhibitors in relation to TGF-beta receptor modulation in COLO-357 pancreatic cancer cells. TGF-beta1 inhibited the growth of COLO-357 cells in a time- and dose-dependent manner and caused a rapid but transient increase in plasminogen activator inhibitor-I and insulin-like growth factor binding protein-3 mRNA levels. TGF-beta1 caused a delayed but sustained increase in the protein levels of the cyclin-dependent kinase inhibitors p15(Ink4B), p21(Cip1), and p27(Kip1) and a sustained increase in type I and II TGF-beta receptors (TbetaRI and TbetaRII) mRNA and protein levels. The protein synthesis inhibitor cycloheximide (10 microg/ml) completely blocked the TGF-beta1-mediated increase in TbetaRI and TbetaRII expression. Furthermore, a nuclear runoff transcription assay revealed that the increase in receptor mRNA levels was due to newly transcribed RNA. There was a significant increase in TbetaRI and TbetaRII mRNA levels in confluent cells in comparison to subconfluent (</=80% confluent) controls, as well as in serum- starved cells when compared with cells incubated in medium containing 10% fetal bovine serum. COLO-357 cells expressed a normal SMAD4 gene as determined by Northern blot analysis and sequencing. These results indicate that TGF-beta1 modulates a variety of functions in COLO-357 cells and up-regulates TGF-beta receptor expression via a transcriptional mechanism, which has the potential to maximize TGF-beta1-dependent antiproliferative responses.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9516449     DOI: 10.1074/jbc.273.13.7495

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  Overexpression of Smad2 and colocalization with TGF-beta1 in human pancreatic cancer.

Authors:  J Kleeff; H Friess; P Simon; S Susmallian; P Büchler; A Zimmermann; M W Büchler; M Korc
Journal:  Dig Dis Sci       Date:  1999-09       Impact factor: 3.199

2.  Transdifferentiation of alveolar epithelial type II to type I cells is controlled by opposing TGF-β and BMP signaling.

Authors:  Lan Zhao; Min Yee; Michael A O'Reilly
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-07-05       Impact factor: 5.464

3.  Deletion of Rb accelerates pancreatic carcinogenesis by oncogenic Kras and impairs senescence in premalignant lesions.

Authors:  Catherine Carrière; A Jesse Gore; Alixanna M Norris; Jason R Gunn; Alison L Young; Daniel S Longnecker; Murray Korc
Journal:  Gastroenterology       Date:  2011-05-27       Impact factor: 22.682

4.  14-3-3sigma Modulates pancreatic cancer cell survival and invasiveness.

Authors:  Divas Neupane; Murray Korc
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

5.  Desmoplastic reaction influences pancreatic cancer growth behavior.

Authors:  Mark Hartel; Fabio F Di Mola; Andrea Gardini; Arthur Zimmermann; Pierluigi Di Sebastiano; Ahmed Guweidhi; Paolo Innocenti; Thomas Giese; Nathalia Giese; Markus W Büchler; Helmut Friess
Journal:  World J Surg       Date:  2004-08-03       Impact factor: 3.352

6.  RUNX3 expression in primary and metastatic pancreatic cancer.

Authors:  J Li; J Kleeff; A Guweidhi; I Esposito; P O Berberat; T Giese; M W Büchler; H Friess
Journal:  J Clin Pathol       Date:  2004-03       Impact factor: 3.411

7.  Cdk4/6 inhibition induces epithelial-mesenchymal transition and enhances invasiveness in pancreatic cancer cells.

Authors:  Fang Liu; Murray Korc
Journal:  Mol Cancer Ther       Date:  2012-08-06       Impact factor: 6.261

8.  Intratumoral delivery of shRNA targeting cyclin D1 attenuates pancreatic cancer growth.

Authors:  S J Deharvengt; J R Gunn; S B Pickett; M Korc
Journal:  Cancer Gene Ther       Date:  2009-10-23       Impact factor: 5.987

Review 9.  Implications of growth factor alterations in the treatment of pancreatic cancer.

Authors:  Márk Juhász; Barbara Nitsche; Peter Malfertheiner; Matthias P A Ebert
Journal:  Mol Cancer       Date:  2003-01-07       Impact factor: 27.401

Review 10.  Pathways for aberrant angiogenesis in pancreatic cancer.

Authors:  M Korc
Journal:  Mol Cancer       Date:  2003-01-07       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.